ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PTK7 Antibody-drug Conjugate HWK-007

Its studies are mostly in Endometrial Neoplasms, led by Whitehawk Therapeutics.

Furthest: phase 1, since Feb 11, 20261 company-led study, 1 open or runningNext primary completion: Oct 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Whitehawk Therapeutics11 open or runningphase 1since Feb 11, 2026Feb 11, 2026Oct 2028phase 1 · NCT07444814

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 11, 2026First study: phase 1 study in Endometrial NeoplasmsFirst studyNCT07444814 · 226 planned · United States

Ahead

  1. Oct 2028Primary completion: phase 1 study in Endometrial NeoplasmsNCT07444814

TargetBeta

PTK7 →read by rule
“An antibody-drug conjugate (ADC) composed of an antibody directed against human inactive tyrosine-protein kinase 7 (protein tyrosine kinase 7; PTK7) ”NCIt, by rule

Other programs on PTK7

ProgramCompanyFurthest phaseStudies
Anti-PTK7 Antibody-drug Conjugate SKB518ruleSichuan Kelun Pharmaceuticalphase 23
Anti-PTK7/Exatecan Antibody-drug Conjugate DAY301ruleday-one-biopharmaceuticals-incphase 11
Anti-PTK7/Exatecan Antibody-drug Conjugate LY4175408ruleEli Lillyphase 11
Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034ruleideaya-biosciencesphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07444814Endometrial Neoplasms · United States1RecruitingOct 2028226

How it is read

Names in the registry

  • “HWK-007”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.